| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/16/2007 | EP1784190A1 Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides |
| 05/16/2007 | EP1784189A1 Modulators of hcv replication |
| 05/16/2007 | EP1784188A2 Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 05/16/2007 | EP1784187A2 Androgen receptor modulators |
| 05/16/2007 | EP1784186A2 Methods for treating or preventing erectile dysfunction or urinary incontinence |
| 05/16/2007 | EP1784185A2 Chemical compounds |
| 05/16/2007 | EP1784184A2 The use of n-aryl diazaspiracyclic compounds in the treatment of addiction |
| 05/16/2007 | EP1784183A2 Processes for the preparation of isothiazole derivatives |
| 05/16/2007 | EP1784182A1 2-sulfanyl-benzimidazol-1-yl-acetic acid derivatives as crth2 antagonists |
| 05/16/2007 | EP1784181A1 Vegf inhibition |
| 05/16/2007 | EP1784180A2 2-amino 1h imidazo ring systems and methods |
| 05/16/2007 | EP1784179A2 Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events |
| 05/16/2007 | EP1784178A1 Aryl (or heteroaryl) azolylcarbinols |
| 05/16/2007 | EP1784177A2 Novel formulation for l-tryptophane comprising carbidopa/benserazide |
| 05/16/2007 | EP1784176A1 Composition comprising lactic acid and lactoferrin |
| 05/16/2007 | EP1784175A2 Inhibitors of akt activity |
| 05/16/2007 | EP1784174A1 A pharmaceutical composition comprising gabapentin |
| 05/16/2007 | EP1784173A1 Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives |
| 05/16/2007 | EP1784172A2 Cancer chemotherapy |
| 05/16/2007 | EP1784171A1 Topical otic compositions and methods of topical treatment or prevention of otic infections |
| 05/16/2007 | EP1784169A1 Polymeric adhesive matrix with salified carboxylic groups for transdermal use |
| 05/16/2007 | EP1784166A2 Compositions comprising 5-amino-2-hydroxybenzoic acid and a reducing sugar |
| 05/16/2007 | EP1784164A2 Methods for transmembrane treatment and prevention of otitis media |
| 05/16/2007 | EP1784161A1 Controlled-release formulation comprising tamsulosin hydrochloride |
| 05/16/2007 | EP1699799B1 Control of parasites in animals by the use of imidazo [1,2-b]pyridazine derivatives |
| 05/16/2007 | EP1684752B1 Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists |
| 05/16/2007 | EP1615634B1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| 05/16/2007 | EP1587788B1 2,7-substituted indoles and their use as 5-ht6 modulators |
| 05/16/2007 | EP1569634B1 Use of a ppar-alpha agonist and metformin for the treatment of obesity |
| 05/16/2007 | EP1534712B1 Pyrazolo[1,5-a]pyrimidine compounds as cyclin dependent kinase inhibitors |
| 05/16/2007 | EP1487981B1 Growth regulating proteins |
| 05/16/2007 | EP1465638B1 Phosphate transport inhibitors |
| 05/16/2007 | EP1455605B1 Soft drink replacer |
| 05/16/2007 | EP1453846B1 14 or 15 membered macrolides with antibacterial activity |
| 05/16/2007 | EP1448544B1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 05/16/2007 | EP1434485B1 Nicotinic acid-heterocyclyl-amides and analogous pyrimidine derivatives for use as pesticides |
| 05/16/2007 | EP1334115B1 Phenanthridine derivatives and antitumoral medicaments containing phenanthridine |
| 05/16/2007 | EP1306373B1 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient |
| 05/16/2007 | EP1305285B1 N-substituted indoles useful in the treatment of diabetes |
| 05/16/2007 | EP1303307B1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 05/16/2007 | EP1265900B1 1,5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-d|pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| 05/16/2007 | EP1262181B1 Use of isothiazole derivatives as urease inhibitors for the treatment of helicobacter pylori induced gastrointestinal diseases |
| 05/16/2007 | EP1147188B1 Internal ribosome entry site (ires), vector containing same and the uses thereof |
| 05/16/2007 | EP1140136B1 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 05/16/2007 | EP1127150B1 Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| 05/16/2007 | EP1115405B1 Use of tnf-alpha inhibitors for treating nerve root injury |
| 05/16/2007 | EP0989853B1 Self-regulated apoptosis of inflammatory cells by gene therapy |
| 05/16/2007 | EP0930894B1 Induction of rev and tat specific cytotoxic t-cells for prevention and treatment of human immunodeficiency virus (hiv) infection |
| 05/16/2007 | EP0789567B1 A method for treating vascular headaches |
| 05/16/2007 | DE202006018609U1 Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung Use of opioid formulations needleless devices for drug delivery |
| 05/16/2007 | DE202006005924U1 Zusammensetzung zur Behandlung von Rhinitis Composition for the treatment of rhinitis |
| 05/16/2007 | CN1964985A 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof |
| 05/16/2007 | CN1964984A Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof |
| 05/16/2007 | CN1964979A Novel water-soluble prodrug |
| 05/16/2007 | CN1964978A Furanopyrimidine compounds effective as potassium channel inhibitors |
| 05/16/2007 | CN1964975A Hiv整合酶抑制剂 Hiv integrase inhibitors |
| 05/16/2007 | CN1964973A Pyrrazolo-pyrimidine derivatives |
| 05/16/2007 | CN1964971A Amino-halogen-imidazopyridines as proton pump inhibitors |
| 05/16/2007 | CN1964970A Iap的抑制剂 Iap inhibitors |
| 05/16/2007 | CN1964969A Fused ring NK1 antagonists |
| 05/16/2007 | CN1964968A 1-aza-bicyclo[3.3.1]nonanes |
| 05/16/2007 | CN1964967A Lewis acid mediated synthesis of cyclic esters |
| 05/16/2007 | CN1964966A Rosiglitazone phosphate and polymorphic forms |
| 05/16/2007 | CN1964965A Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| 05/16/2007 | CN1964964A Piperidine derivates for the treatment of chemokines mediared disease |
| 05/16/2007 | CN1964963A Hydroxamates, their manufacture and use as pharmaceutical agents |
| 05/16/2007 | CN1964962A Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors |
| 05/16/2007 | CN1964958A Novel alkyl substituted piperazine derivatives used as monoamine neurotransmitter re-uptake inhibitors |
| 05/16/2007 | CN1964956A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 05/16/2007 | CN1964955A Small molecules for treatment of hypercholesterolemia and related diseases |
| 05/16/2007 | CN1964954A 吡唑并嘧啶类 Pyrazolo pyrimidine |
| 05/16/2007 | CN1964953A Novel 3-phenyltetrahydrocinnolin-5-ol derivative and medicinal use thereof |
| 05/16/2007 | CN1964952A Pyridazin-3(2h)-one derivatives and their use as PDE4 inhibitors |
| 05/16/2007 | CN1964950A Propane-1,3-dione derivative or its salt |
| 05/16/2007 | CN1964948A Therapeutic agents |
| 05/16/2007 | CN1964947A Pyrazole derivatives, compositions containing such compounds and methods of use |
| 05/16/2007 | CN1964944A Indole derivatives as antiviral agents |
| 05/16/2007 | CN1964940A Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| 05/16/2007 | CN1964743A Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide |
| 05/16/2007 | CN1964742A Combination therapy with azd2171 and 5-fu and/or cpt-11 |
| 05/16/2007 | CN1964741A Methods of using molecules related to organic cation transporter 3 (OCT3) for treating depression, anxiety neuroses, drug dependencies, and other similar mental disorders |
| 05/16/2007 | CN1964736A Dalbavancin compositions for treatment of bacterial infections |
| 05/16/2007 | CN1964734A Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit |
| 05/16/2007 | CN1964733A Novel use of peptide compounds for treating essential tremor and other tremor syndromes |
| 05/16/2007 | CN1964731A Treatment or prevention of respiratory viral infections with immunomodulator compounds |
| 05/16/2007 | CN1964728A Compositions for correcting age related changes of a human endocrine system and methods for producing a pharmaceutical form bases on said compositions |
| 05/16/2007 | CN1964725A Therapeutic delivery system comprising a high molecular weight PEG-like compound |
| 05/16/2007 | CN1964724A Solid dosage form of wetted heparin |
| 05/16/2007 | CN1964723A Agent for visualizing transparent tissue |
| 05/16/2007 | CN1964722A Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies |
| 05/16/2007 | CN1964721A A medical solution, a method for producing said medical solution and use thereof |
| 05/16/2007 | CN1964720A Transgenic models of alzheimer's disease and uses therefor in the treatment of a variety of neurodegenerative diseases |
| 05/16/2007 | CN1964719A Use of loteprednol etabonate for the treatment of dry eye |
| 05/16/2007 | CN1964718A Leptomycin compounds |
| 05/16/2007 | CN1964717A Substituted cinnolin-4-ylamines |
| 05/16/2007 | CN1964716A Isoquinoline derivatives and methods of use thereof |
| 05/16/2007 | CN1964715A Methods for treating arthritic conditions in dogs |
| 05/16/2007 | CN1964714A Combination methods of treating cancer |
| 05/16/2007 | CN1964713A Co-administration of dopamine-receptor binding compounds |
| 05/16/2007 | CN1964712A Selective androgen receptor modulators and methods of use thereof |